Novartis has strengthened its warnings about possible liver failure during treatment with deferasirox (Exjade), an iron-chelating medicine used to remove excess iron, for example in people who have frequent blood transfusions.
The company stresses that the dose should be adjusted, or treatment stopped, if blood levels of liver enzymes (transaminases) rise. Patients on deferasirox need regular blood tests of liver and kidney function.
0
Like
0
Love
0
Angry
0
Dislike
0
